Why attend?
Build relationships with leading VCs, institutional investors, and startup founders actively deploying capital into longevity and biotech.
Experience Lighthaven – longevity style. An intimate, inspiring environment designed for high-impact discussions and health. Whiteboards meets sauna + cold plunge.
Get early access to emerging startups, cutting-edge biotech ventures, and investment opportunities shaping the future of longevity.
Gain insights from top investors, fund managers, and biotech founders on the most promising opportunities in longevity and healthspan innovation.
Schedule
(tentative)
Buy a ticket
Regular
Longevity Investors Forum (May 2 - 8)
$525
VIP
Longevity Investors Forum (May 2 - 8)
$1575
Speakers

Omri Amriav-Drory is a scientist and entrepreneur, currently serving as the General Partner at NFX Bio. He is the Founder and CEO of Renewal Bio, a company focused on developing innovative solutions in the field of biotechnology. Omri previously founded Genome Compiler, which was acquired by Twist Bioscience, and has played a pivotal role in scaling and investing in influential techbio companies. His unique blend of scientific expertise and entrepreneurial experience makes him a significant figure in the techbio industry.


Anastasiya Giarletta is a prominent figure in the longevity and biotech sectors, serving as an advisor and co-founder of Aikora Health and an investor at R42 Group. Based in Silicon Valley and London, she focuses on connecting venture funds, angels, and entrepreneurs within the early-stage longevity ecosystem. Anastasiya is also a Teaching Assistant at Stanford University School of Medicine, where she lectures on Longevity Venture Capital and Healthcare Venture Capital. Her extensive network and expertise make her a key influencer in advancing healthcare and human aging technologies.


Phil Newman is the Founder and CEO of Longevity.Technology, a leading media and investment platform focused on the longevity megatrend. He has held multiple C-level management positions, applying his marketing and business development expertise in sectors such as longevity, IoT, bionics, medical devices, biopharma, and 3D manufacturing. Phil's work aims to bring together innovators and investors to commercialize companies that will form the longevity economy.


Daniel Ives is the CEO and founder of Shift Bioscience, a company dedicated to reversing cellular aging using AI-guided cellular rejuvenation techniques. With a background in mitochondrial biology from the University of Cambridge, Daniel has been at the forefront of developing innovative solutions to combat age-related diseases. His work focuses on leveraging advanced machine learning and epigenetic aging clocks to discover new therapeutic interventions that can extend human healthspan.


Dr. Emil Kendziorra is the Founder and CEO of Tomorrow.Bio, a startup dedicated to advancing biostasis (cryonics) research and providing human cryopreservation services. He graduated summa cum laude from the University of Göttingen and has extensive experience in cancer research and entrepreneurship. Dr. Kendziorra has founded and led multiple tech and medical startups, including MedLanes and onFeedback. His vision is to build an organization that significantly contributes to the field of cryonics and promotes public awareness about its potential.


Karl Pfleger is a prominent angel investor and advocate for longevity research, known for his significant contributions to the biotech industry. He is an investor in Repair Biotechnologies, focusing on gene therapy for age-related diseases, and runs Aging Biotech Info, a valuable resource for the longevity community. Karl's background in machine learning and his dedication to supporting groundbreaking research make him a key figure in the fight against aging.


Ole Mensching, Ph.D., is the co-founder and General Partner of Apollo Ventures, a venture capital fund dedicated to aging and age-related diseases. He has a strong background in investment and operations, previously co-founding CareerTeam, a successful headhunting agency. Ole holds a Ph.D. from the University of California, Berkeley, and the University of Cologne, and his expertise in HR and team building has been instrumental in supporting Apollo's portfolio companies.


Sebastian Brunemeier is a biotech venture capitalist and company builder focused on longevity and regenerative medicine. He is the co-founder and General Partner of Healthspan Capital and the CEO and founder of ImmuneAGE Bio, a company dedicated to immune system rejuvenation. Sebastian has co-founded several longevity biotech companies, contributing to significant advancements in the field. His extensive experience and dedication to improving human healthspan have made him a respected figure in the biotech industry.


David Gobel is a philanthropist, entrepreneur, inventor, and futurist, best known for co-founding the Methuselah Foundation, which focuses on extending healthy human lifespans through regenerative medicine and biotechnology. He has been a driving force in promoting the concept of longevity escape velocity and has supported numerous projects and companies aimed at combating age-related diseases. David's visionary work continues to inspire advancements in the field of life extension.


Anar Isman is the co-founder and CEO of AgelessRx, a telemedicine platform dedicated to slowing down the aging process through scientifically-backed interventions. With a background in investment management, Anar transitioned to the field of longevity science driven by a desire to make a meaningful impact on human health. He believes in making cutting-edge longevity treatments accessible to everyone and is passionate about advancing the field to help people live healthier, longer lives.


Aykut Karaalioglu is an accomplished entrepreneur and investor, best known for founding MobileAction, a company specializing in app discovery and optimization. He has held various leadership roles, including CEO of SearchAds.comand Growth Lead at ScoreBeyond. Aykut is also an active angel investor and advisor to several startups, leveraging his extensive experience in product management and user acquisition to drive innovation and growth in the tech industry.


Matthew "Oki" O'Connor is the Co-CEO of Cyclarity Therapeutics, a company focused on developing treatments for cardiovascular diseases through innovative cyclodextrin technology. With a Ph.D. in Biochemistry and extensive research experience in aging and regenerative medicine, O'Connor has made significant contributions to the field. His work aims to eliminate toxic oxidized cholesterol, a major factor in atherosclerosis, and improve overall healthspan.


Mac Davis is the founder of Minicircle, a pioneering company focused on revolutionizing gene therapy. With a mission to enhance human health and sovereignty, he developed a reversible human genetic enhancement protocol that uses non-inflammatory, non-heritable plasmids to safely introduce genes into the body without altering the genome. Mac’s innovative approach challenges traditional medical practices, offering a fast, accessible, and ethical alternative to lifelong treatments. His work aims to empower individuals and communities, ensuring that gene therapy is available to all, free from the constraints of the current healthcare system.


Parmita Mishra is a computational biologist and entrepreneur, known for founding Precigenetics, a company focused on developing advanced non-invasive diagnostic tools that integrate biophotonics with machine learning. She is dedicated to pushing the boundaries of healthcare technology, particularly in the field of non-invasive cancer diagnostics. Parmita's work aims to enhance the identification of molecular signatures unique to cancerous cells, leveraging machine learning algorithms to improve detection and classification.

Kevin Caldwell is the co-founder, President, and CEO of Ossium Health, a pioneering bioengineering company focused on creating the world's first bone marrow bank for transplants. With a background in physics and economics from MIT and a JD from Harvard Law School, Kevin has also worked as an Engagement Manager at McKinsey and a Senior Investment Associate at Bridgewater Associates. His diverse experience and dedication to improving human health through innovative solutions make him a significant figure in the biotech industry.
Nish Bhat is an entrepreneur and investor with extensive experience in biotechnology and venture capital. He is the Founder and General Partner of Carbon Silicon Ventures, a firm dedicated to supporting startups that integrate engineering principles with biological sciences to drive innovation in healthcare. Before establishing Carbon Silicon Ventures, Mr. Bhat co-founded Color Health, Inc. in 2013, a company specializing in genetic testing services for various hereditary cancers. He also co-founded SciFounders, a venture capital firm launched in 2021, and serves on the board of Reference Medicine, a company focused on making specimens more affordable and accessible for oncology diagnostic developers. His journey reflects a commitment to advancing the intersection of biology and engineering, aiming to transform healthcare through innovative solutions.
Dr. Dave Messina is an entrepreneur and scientist with over 25 years of experience in computational biology and human genetics. He serves as General Partner at Pioneer Fund and leads the Future of Health Fund. Prior to joining Pioneer Fund, Dr. Messina co-founded Cofactor Genomics, a company specializing in RNA and machine-learning-based diagnostics, where he led the development and clinical application of innovative diagnostic tools. Through his leadership at Pioneer Fund, he aims to advance the development of innovative health and biotechnology solutions, leveraging his extensive experience to support groundbreaking startups in the industry.

Boyang Wang is an entrepreneur and investor with a strong background in computer science and a passion for the gaming and longevity industries. He is the founder of Immortal Dragons, a purpose-driven longevity fund dedicated to advancing research and innovation in life extension technologies. In addition to his entrepreneurial ventures, Boyang actively contributes to the longevity community. He serves as a senior venture fellow at Healthspan Capital, one of the most active longevity-focused venture capital funds. His engagement extends to speaking at conferences and participating in podcasts, where he shares insights on the convergence of technology, gaming, and life extension. Through his diverse endeavors, Boyang Wang continues to influence both the gaming industry and the field of longevity, driving forward initiatives that blend technological advancement with human health and well-being.


Edward Lando is an entrepreneur and investor with a focus on early-stage startups. He is the founder of Pareto Holdings, a venture studio and investment firm that has incubated over 10 companies and invested in more than 25 unicorns. In addition to his work at Pareto Holdings, Edward has co-founded several companies across various industries. He is also an active angel investor, with a portfolio that includes over 100 investments and 21 exits. Through his ventures and investments, Edward aims to empower innovative founders and contribute to the growth of transformative companies.


Chris Bradley is a serial entrepreneur and technologist with over 15 years of experience in biotech, health IT, and artificial intelligence. He is the founder and CEO of Matter Bio, a longevity-focused company dedicated to preserving genome integrity to combat aging and age-related diseases. Matter Bio employs a hub-and-spoke model to advance multiple scientific breakthroughs, including accurate mutation sequencing, reversal of somatic mutations, and clearance of pathological cells. Under his leadership, the company had a successful closing of seed round funding for the start of a clinical trial in solid state cancer.

Winnie Qiu is the investment director of Paramita VC, co-founder of Avinasi Labs, the 1st AI-native data layer for longevity, which uses Web3 technology and decentralized users’ experiment to help scientists solve data accessibility bottlenecks in longevity research. She previously founded Haalthy, a company using data to assist over 100,000+ cancer patients to get access to new treatment 14 months in advance & saved over 300 million RMB in medical cost. She previously led a hardware (in healthcare) incubator at XbotPark, which incubated 80+ hardware startups and 8 unicorns in 8 years. Winnie received her master in engineering degree from MIT.
Priscila Chiavellini is a postdoctoral researcher in the Sebastiano Lab at Stanford University. She earned her Ph.D. from the Universidad Nacional de La Plata in Argentina, where she studied brain partial reprogramming in aged female rats as a strategy to reverse cognitive decline. Nearly two years ago, she joined Dr. Sebastiano's lab to investigate reproductive aging and explore partial reprogramming as a potential method to address it. Her current research is supported by a postdoctoral fellowship from the Stanford Maternal and Child Health Research Institute.
Dr. Aimee Eyvazzadeh is a reproductive endocrinologist and fertility specialist with over two decades of experience in clinical practice and public health education. Based in the San Francisco Bay Area, she is the founder of The Egg Whisperer brand and hosts a globally recognized fertility podcast and video series. Dr. Aimee is known for her innovative approaches to fertility care, including the TUSHY Method—a comprehensive diagnostic framework—and the Egg Freezing Party initiative, which aims to make fertility preservation more accessible and less stigmatized. She earned her M.D. from the David Geffen School of Medicine at UCLA, completed her residency in Obstetrics and Gynecology at Harvard Medical School, and pursued a fellowship in Reproductive Endocrinology and Infertility. Additionally, she holds a Master’s in Public Health Management and Policy from the University of Michigan.
About
The Longevity Investors Summit brings together the next generation of investors and founders turning breakthrough science into investable opportunities.
Key focus areas
Longevity Investor Week
@Vitalist Bay
01. Longevity biotech
Investing in breakthrough therapies, regenerative medicine, and age-related disease prevention.
02. Venture trends
Understanding where funding is going and how investors are shaping the longevity landscape
03. Emerging startups
Spotlighting the most promising longevity and biotech companies seeking investment.
04. Regulation and risk
Navigating the challenges of biotech investment, from clinical trials to market adoption.
05. Investment strategies
Exploring the best approaches for deploying capital in a rapidly evolving industry.
Venue
Lighthaven Campus, Berkeley California. A beautifully designed environment for discussion, collaboration, and learning.
📍Address: 2740 Telegraph Avenue, Berkeley, CA.